Bausch & Lomb licenses glaucoma candidate from NicOx for up to $180 million
This article was originally published in Scrip
NicOx has signed a licensing agreement which grants Bausch & Lomb exclusive worldwide rights to develop and commercialise NCX 116, a nitric oxide-donating prostaglandin F2α-analogue, which has completed two Phase II studies in patients with glaucoma and ocular hypertension.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.